Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | NAAA | Q02083 | 2/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.35 |
| ▸ | CTSG | P08311 | 2/20 | 0.35 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.35 |
| ▸ | CMA1 | P23946 | 2/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11587804 | 0.89 | GPR84 (0.44) | CSNK1ECES2CES1NAAAPRSS1 | |
| SCHEMBL28204364 | 0.89 | GPR84 (0.44) | CSNK1ECES2CES1NAAAPRSS1 | |
| SCHEMBL490946 | 0.85 | ACE2 (0.43) | CSNK1ECES2CES1NAAAPRSS1 | |
| SCHEMBL5706448 | 0.82 | MEN1 (0.33) | — | |
| SCHEMBL5706444 | 0.81 | CSNK1E (0.40) | CSNK1ECES2CES1NAAAPRSS1 | |
| SCHEMBL5711544 | 0.81 | MMP2 (0.45) | CSNK1ECES2CES1NAAAPRSS1 | |
| SCHEMBL5706433 | 0.78 | MEN1 (0.38) | ALDH1A1 | |
| SCHEMBL7597024 | 0.77 | CES2 (0.41) | CSNK1ECES2CES1NAAAPRSS1 | |
| SCHEMBL8903692 | 0.77 | CES2 (0.41) | CSNK1ECES2CES1NAAAPRSS1 | |
| SCHEMBL2279350 | 0.76 | CSNK1E (0.41) | CSNK1ECES2CES1NAAAPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1566175-B1 | Topical preparation comprising at least one aryloxime and bisabolol | MERCK PATENT GMBH (DE) | 2006-10-25 | — | — | EP | claimed |
| US-20050249761-A1 | Topical composition comprising at least one aryl oxime and bisabolol | MERCK PATENT GESELLSCHAFT MIT BECHRANKTER HAFTUNG (DE) | 2005-11-10 | — | — | US | claimed |
| EP-0149242-B1 | 1-(2-HYDROXYARYL)-ALCAN-1-ONE OXIME, PREPARATION AND PHARMACEUTICAL USE | CHEMISCHE UND PHARMAZEUTISCHE FABRIKEN FAHLBERG-LIST GmbH (DE) | 1990-10-31 | — | — | EP | claimed |
| US-4816487-A | ANTIALLERGENS | HUMBOLDT-UNIVERSITAET ZU BERLIN (DD) | 1989-03-28 | — | — | US | claimed |
| US-20050249761-A1 | Topical composition comprising at least one aryl oxime and bisabolol | MERCK PATENT GESELLSCHAFT MIT BECHRANKTER HAFTUNG (DE) | 2005-11-10 | — | — | US | disclosed |
| US-20030187034-A1 | Composition containing at least one aryl oxime and at least one active substance for treating acne and the use thereof | MERCK PATENT GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-20030176470-A1 | Topical composition containing at least one aryl oxime, and method for the preparation thereof | MERCK PATENT GMBH (DE) | 2003-09-18 | — | — | US | disclosed |
| US-20030157037-A1 | Use of aryl oximes for the prophylaxis and/or treatment of erythema formation and/or inflammatory reaction of the skin | MERCK PATENT GMBH (DE) | 2003-08-21 | — | — | US | disclosed |
| EP-0149242-B1 | 1-(2-HYDROXYARYL)-ALCAN-1-ONE OXIME, PREPARATION AND PHARMACEUTICAL USE | CHEMISCHE UND PHARMAZEUTISCHE FABRIKEN FAHLBERG-LIST GmbH (DE) | 1990-10-31 | — | — | EP | disclosed |
| US-4816487-A | ANTIALLERGENS | HUMBOLDT-UNIVERSITAET ZU BERLIN (DD) | 1989-03-28 | — | — | US | disclosed |
| EP-0149242-A2 | 1-(2-Hydroxyaryl)-alcan-1-one oxime, preparation and pharmaceutical use | CHEMISCHE UND PHARMAZEUTISCHE FABRIKEN FAHLBERG-LIST GmbH (DE) | 1985-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030157037-A1 | Use of aryl oximes for the prophylaxis and/or treatment of erythema formation and/or inflammatory reaction of the skin | CYP8B1, CBR3, CYP2C8 | CSNK1E 565/4885CES2 164/4885CES1 114/4885 |
| US-20030187034-A1 | Composition containing at least one aryl oxime and at least one active substance for treating acne and the use thereof | CYP8B1, ACOX3, ACOX1 | CSNK1E 299/4885CES2 195/4885CES1 244/4885 |
| US-20030176470-A1 | Topical composition containing at least one aryl oxime, and method for the preparation thereof | MGLL, LIPA, GLO1 | CSNK1E 561/4885CES2 580/4885CES1 420/4885 |
| US-20050249761-A1 | Topical composition comprising at least one aryl oxime and bisabolol | TYR, CYP1B1, AHR | CSNK1E 1692/4885CES2 147/4885CES1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.